

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A method for predicting an increased risk for onset of glaucoma in a subject, comprising assaying for the presence of ~~A gene assay method comprising the steps of: detecting a mutation of at least one nucleotide base in the coding region of an optineurin (OPTN) gene of said a human subject, wherein when said mutation is present, said subject is predicted to have an increased risk for onset of glaucoma; and predicting future onset of glaucoma in the subject using the mutation as an index.~~
2. (currently amended) The ~~gene assay method~~ of claim 1, wherein the coding region of ~~said glaucoma-related gene is an~~ OPTN gene comprises nucleotides 1 to 1734 of ~~has a nucleic acid sequence denoted by~~ SEQ ID NO: 1.
3. (currently amended) The ~~gene assay method~~ of claim 2, wherein said mutation is a substitution of G for A at position 619 ~~and/or~~ a substitution of A for G at position 898, or both, ~~in the nucleic acid sequence denoted by~~ SEQ ID NO:1.
4. (currently amended) The ~~gene assay method~~ of claim 2, wherein said mutation is a deletion of one or more nucleotides in ~~bases in the nucleic acid sequence denoted by~~ SEQ ID NO: 1.
5. (currently amended) The ~~gene assay method~~ of claim 2, wherein said mutation is an insertion of one or more nucleotides in ~~bases in the nucleic acid sequence denoted by~~ SEQ ID NO: 1.

6. (currently amended) The ~~gene assay~~ method of claim 2, wherein said mutation is two or more substitutions of nucleotides in bases in the nucleic acid sequence denoted by SEQ ID NO: 1.

7. (currently amended) The ~~gene assay~~ method according to claim 1, wherein the said glaucoma is primary open angle glaucoma and/or normal ocular tension glaucoma, or both.

8. (currently amended) The ~~gene assay~~ method according to claim 1, wherein the said assay is carried out mutation is detected by using an oligonucleotide that hybridizes to a selected portion capable of forming a hybrid at a specific position of the coding region of the OPTN gene.

9. (canceled).

10. (currently amended) A ~~gene assay~~ method for predicting an increased risk for future-onset of primary open angle glaucoma and/or normal ocular tension glaucoma, or both, in a subject, comprising the steps of:

(a) ~~isolating a polynucleotide sample from a subject suspected of having a mutation in a glaucoma-related gene,~~

(~~a~~) performing a nucleic acid amplification process on a polynucleotide sample from a subject said polynucleotide using at least one oligonucleotide primer pair, wherein said primer oligonucleotide pair comprises a member selected from the group consisting of oligonucleotides comprising sequences as follows:

(1) an oligonucleotide primer pair consisting of nucleotide sequences a base sequence represented by (i) 21 and 22, and (ii) 27 and 28 ~~any of SEQ ID NOs: 15 to 40;~~

(2) an oligonucleotide primer pair wherein each member of said pair is a complement of one member a complementary chain of an oligonucleotide primer pair according to (1);

(3) an oligonucleotide primer pair wherein each member of said pair that hybridizes with one member of an oligonucleotide primer pair according to (1) or (2) under stringent conditions;

(4) an oligonucleotide primer pair wherein each member of said pair has having a homology of 60% or more to a respective member of to an oligonucleotide primer pair according to any one of (1) to (3); and

(5) an oligonucleotide primer pair according to any one of (1) to (4) wherein each member of said pair has at least one nucleotide having one to several bases mutated by substitution, deletion, insertion or addition mutation,

(be) detecting a mutation of at least one base nucleotide in the coding region of the amplification product of (a) a glaucoma-related gene; and

(d) wherein when said mutation is detected, said subject is predicted to have an increased risk for onset of primary open angle glaucoma or normal ocular tension glaucoma, or both predicting future onset of primary open angle glaucoma and/or normal ocular tension glaucoma using the mutation as an index.

11. (canceled).

12. (new) The method according to claim 10, wherein said at least one oligonucleotide primer pair amplifies a selected portion of the coding region of an OPTN gene comprising nucleotides 1 to 1734 of SEQ ID NO: 1

13. (new) The method of claim 12, wherein said mutation is a substitution of G for A at position 619 or a substitution of A for G at position 898, or both, in SEQ ID NO:1.